Novo Nordisk A/S

NYSE:NVO Stock Report

Market Cap: US$354.9b

Novo Nordisk Management

Management criteria checks 3/4

Novo Nordisk's CEO is Lars Jorgensen, appointed in Jan 2017, has a tenure of 8.42 years. directly owns 0.015% of the company’s shares, worth $52.31M. The average tenure of the management team and the board of directors is 3.3 years and 7.3 years respectively.

Key information

Lars Jorgensen

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure8.4yrs
CEO ownership0.01%
Management average tenure3.3yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

Novo Nordisk: The Time To Buy Has Come

Jun 10

Novo Nordisk: Examining Tariff And Pricing Risks

Apr 26

Novo Nordisk: A Price Too Low To Ignore

Apr 18

Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors

Mar 30

Novo Nordisk: CagriSema Disappoints Again

Mar 10

Why Novo Nordisk Is A Strong Buy Despite Market Concerns

Feb 20

Novo Nordisk: Dips Like These Come Once Every Few Years

Feb 13
author-image

Novo Nordisk aims for a promising future with a fair value of 101.75

Revenue growth is expected to be driven by continued demand for GLP-1 drugs, especially Ozempic and Wegovy.

Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today

Feb 05

Novo Nordisk: Excellent Opportunity To Buy The Dip

Jan 15

Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential

Jan 06

Novo Nordisk Stock: A Rare Buying Opportunity

Dec 20

Novo Nordisk: Just The Right Price (Rating Upgrade)

Dec 11

Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial?

Nov 25

Novo Nordisk: A GLP-1 Leader Faces Increasing Competition

Nov 06

Novo Nordisk: A Diabetes Leader Among Big Pharma, But Still Overvalued

Oct 21

Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy

Sep 18

Novo Nordisk: Low Dividend Yield, Decelerated Growth Rates, Hold For Now

Sep 10

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

Aug 18

Novo Nordisk: Growth Only Limited By Manufacturing Capacity

Aug 07

Novo Nordisk: Better Buying Opportunities Ahead

Jul 26

Novo Nordisk: Buy On Dips

Jul 04

Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy

Jun 26

Novo Nordisk: Leading The Fight Against Diabetes And Obesity

Jun 18

Novo Nordisk: Considerable Growth Beyond Ozempic

May 27

The FTC Cracks Down On Novo Nordisk's Ozempic

May 03

Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy

Apr 26

Novo Nordisk: The Moat Won't Last Forever

Apr 09

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

Mar 18

CEO Compensation Analysis

How has Lars Jorgensen's remuneration changed compared to Novo Nordisk's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

DKK 105b

Dec 31 2024n/an/a

DKK 101b

Sep 30 2024n/an/a

DKK 95b

Jun 30 2024n/an/a

DKK 90b

Mar 31 2024n/an/a

DKK 89b

Dec 31 2023n/an/a

DKK 84b

Sep 30 2023n/an/a

DKK 75b

Jun 30 2023n/an/a

DKK 67b

Mar 31 2023n/an/a

DKK 61b

Dec 31 2022DKK 60mDKK 17m

DKK 56b

Sep 30 2022n/an/a

DKK 53b

Jun 30 2022n/an/a

DKK 51b

Mar 31 2022n/an/a

DKK 49b

Dec 31 2021DKK 58mDKK 17m

DKK 48b

Sep 30 2021n/an/a

DKK 46b

Jun 30 2021n/an/a

DKK 44b

Mar 31 2021n/an/a

DKK 43b

Dec 31 2020DKK 57mDKK 14m

DKK 42b

Sep 30 2020n/an/a

DKK 42b

Jun 30 2020n/an/a

DKK 41b

Mar 31 2020n/an/a

DKK 40b

Dec 31 2019DKK 55mDKK 14m

DKK 39b

Sep 30 2019n/an/a

DKK 39b

Jun 30 2019n/an/a

DKK 38b

Mar 31 2019n/an/a

DKK 38b

Dec 31 2018DKK 41mDKK 11m

DKK 39b

Compensation vs Market: Insufficient data to establish whether Lars's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Lars's compensation has been consistent with company performance over the past year.

CEO

Lars Jorgensen (59 yo)

8.4yrs
Tenure
DKK 60,100,000
Compensation

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...

Leadership Team

NamePositionTenureCompensationOwnership
Lars Jorgensen
President8.4yrsDKK 60.10m0.015%
$ 52.3m
Karsten Knudsen
Executive VP7.3yrsDKK 21.50m0.0054%
$ 19.1m
Henrik Wulff
Executive VP of CMC & Product Supply and Member of the Management Boardno dataDKK 22.00m0.00079%
$ 2.8m
Martin Lange
Executive VP of Development & Member of the Management Board4.4yrsDKK 20.90mno data
Marcus Schindler
EVP of Research & Early Development4.3yrsDKK 20.90mno data
Maziar Doustdar
Executive VP of International Operations & Member of the Management Boardno datano data0.0019%
$ 6.8m
Ludovic Helfgott
Executive VP of Product & Portfolio Strategy and Member of Management Boardno datano datano data
Tania Sabroe
EVP of People2.3yrsno datano data
David Moore
Executive VP of US Operations & Member of Management Board2.3yrsno datano data
Thilde Bogebjerg
Executive VP of Qualityless than a yearno datano data
Jacob Martin Rode
Head of Investor Relationsno datano datano data
John Kuckelman
Group General Counsel1.2yrsno datano data
3.3yrs
Average Tenure
55yo
Average Age

Experienced Management: NVO's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sylvie Gregoire
Independent Director10.3yrsDKK 1.80m0.00016%
$ 567.8k
Lars Sorensen
Observerless than a yearDKK 26.80mno data
Helge Lund
Independent Chairman of the Board8.3yrsDKK 3.10m0.00014%
$ 496.8k
Henrik Poulsen
Vice Chairman of the Board4.3yrsDKK 2.00m0.00030%
$ 1.1m
Laurence Debroux
Independent Director6.3yrsDKK 2.00m0.000010%
$ 35.5k
Martin MacKay
Independent Director7.3yrsDKK 1.70m0.00015%
$ 532.3k
Andreas Fibig
Independent Director7.3yrsDKK 1.40m0.000030%
$ 106.5k
Kasim Kutay
Non-Independent Director8.3yrsDKK 1.20m0.000010%
$ 35.5k
Liselotte Hyveled
Employee Representative Director3.3yrsDKK 800.00k0.000060%
$ 212.9k
Mette Jensen
Employee Non-Independent Representative Director7.3yrsDKK 1.20m0.000070%
$ 248.4k
Thomas Rantzau
Employee Representative Non-Independent Director7.4yrsDKK 1.00m0.000030%
$ 106.5k
Elisabeth Christensen
Employee Representative Director3.3yrsDKK 800.00k0.000060%
$ 212.9k
7.3yrs
Average Tenure
60yo
Average Age

Experienced Board: NVO's board of directors are considered experienced (7.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/15 07:12
End of Day Share Price 2025/06/13 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novo Nordisk A/S is covered by 71 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
Gerhard SchwarzBaader Helvea Equity Research